
This article was downloaded by: ["Queen's University Libraries, Kingston"] On: 23 August 2014, At: 06:30 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/gpss20

Synthesis of 1-(2,3-Dimethyl-1-phenylpyrazolone-5-yl-4)-2-mercapto-1',5-cycloalkanespiro[1,3]thiazolo[3,4-b]-1,2,4-triazole Derivatives

R. M. Shaker^a

^a El-Minia University, El-Minia, Egypt Published online: 27 Oct 2010.

To cite this article: R. M. Shaker (2003) Synthesis of 1-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4)-2-mercapto-1',5-cycloalkane-spiro[1,3]thiazolo[3,4-b]-1,2,4-triazole Derivatives, Phosphorus, Sulfur, and Silicon and the Related Elements, 178:5, 1175-1182, DOI: <u>10.1080/10426500307854</u>

To link to this article: http://dx.doi.org/10.1080/10426500307854

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions




SYNTHESIS OF 1-(2,3-DIMETHYL-1-PHENYL-PYRAZOLONE-5-yl-4)-2-MERCAPTO-1',5-CYCLOALKANE-SPIRO[1,3]THIAZOLO[3,4-b]-1,2,4-TRIAZOLE DERIVATIVES

R. M. Shaker El-Minia University, El-Minia, Egypt

(Received October 29, 2002; accepted November 23, 2002)

New thiosemicarbazone derivatives **3a–c**, obtained by the condensation of 4-(2,3-dimethyl-1-phenyl-pyrazolone-5-yl-4)-thiosemicarbazide (**1**) with cycloalkanones **2a–c**, on reaction with mercaptoacetic acid (**4**) yields the corresponding spiro thiazolidin-4-ones **5a–c**. Compound **5** undergo intramolecular heterocyclization to the corresponding 1-(2,3-dimethyl-1-phenyl-pyrazolone-5-yl-4)-2-mercapto-1',5cycloalkane-spiro[1,3]thiazolo[3,4-b]-1,2,4-triazoles **6a–c** with NaOH.



Keywords: Spiro thiazolidin-4-ones; synthesis; thiazolo-[3,4-b]-1,2,4-triazoles; thiosemicarbazones


Spiroheterocyclic derivatives have considerable importance as drugs and a wide scope of applications.^{1–5} The pharmaceutical activities of 1,2,4-triazoles^{6–9} and thiazole derivatives^{10–12} have been studied extensively. Prompted by the aforesaid biological and pharmaceutical activities, and in continuation of our previous work aimed at

Address correspondence to R. M. Shaker, Chemistry Department, Faculty of Science, El-Minia University, El-Minia, Egypt.

developing new approaches for the synthesis of polyfunctionally substituted heterocyclic compounds of expected biological activity,^{12–17} we report here the synthesis of the versatile and hitherto unreported, otherwise difficult accessible bicyclic system 2-mercapto-1',5-cycloalkanespiro[1,3]thiazolo[3,4-b]-1,2,4-triazoles **6a–c** in order to study their biological activity.

RESULTS AND DISCUSSION

Thus, 1-cycloalkylidene-4-(2,3-dimethyl-1-phenylpyrazolone-5-yl-4)thiosemicarbazones 3a-c were synthesized by condensation of 4-(2,3-dimethyl-1-phenyl-pyrazolone-5-yl-4)-thiosemicarbazide (1) with cycloalkanones 2a-c in butanol containing a catalytic amount of gl. acetic acid (Scheme 1). The structural assignments of compound **3**



SCHEME 1

was confirmed by elemental analysis as well as by IR, MS, ¹H NMR, and ¹³C NMR spectra. The resonance peak of NH₂ group appearing at δ 4.72 ppm in the ¹H NMR of **1** disappeared in the ¹H NMR of **3** supporting the participation of this group in the hydrazone formation (see Experimental). The ¹³C NMR spectrum of **3a** confirmed the proposed structural feature (Figure 1).

Addition-condensation of thiosemicarbazones **3** to mercaptoacetic acid (**4**) furnished the corresponding cycloalkane spirothiazolidin-4ones **5a–c** (Scheme 1). The products were fully characterized through spectral and elemental analysis (see Experimental), the structure of **5** was indicated by broad IR bands around 3320 cm⁻¹ corresponding to NH group, at 1685, 1650 cm⁻¹ corresponding to the carbonyl group of the thiazole and pyrazole rings, and a band around 1220 cm⁻¹ corresponding to C=S group. The structure elucidation for the system **5** shall be discussed here in detail for **5a**. The ¹H NMR spectrum in DMSO-d₆ contained a two protons singlet at δ 3.52 due to thiazolidinone protons, a two sharp singlet at δ (2.15 and 3.09) for the two methyl groups, a broad




FIGURE 1 ¹³C NMR spectral data.

singlet at δ 11.9 for the two NH groups, a ten-protons multiplet in the region of δ 1.15–2.10 due to the cyclohexyl protons and a multiplet at δ 7.2–7.4 ppm for the aromatic protons. The structure **5a** was further confirmed by ¹³C NMR spectrum which revealed resonance at δ 53.5 and 164.6 ppm. The resonances were consistent with the quaternary sp³ carbon (spiro carbon) and the carbonyl group of the thiazole ring respectively (Figure 1). Furthermore, the mass spectrum of **5a** gave the molecular ion peak at m/z 431 (M⁺, 78%) which found to be in good agreement with the assigned structure (see Experimental).

The compound 5a on treatment with sodium hydroxide underwent cyclization to 1-(2,3-dimethyl-1-phenyl-pyrazolone-5-yl-4)-2mercapto-1',5-cyclohexane-spiro[1,3]thiazolo[3,4-b]-1,2,4-triazole (6a) (Scheme 1). The structural assignment of 6a was established by spectroscopic studies and elemental analysis. Thus, the mass spectrum of **6a** was compatible with the molecular formula $C_{20}H_{23}N_5OS_2$ (M⁺ = 413). Its IR spectrum indicated that it exist in the iminothiol-form 6α : There is no absorption of the N-C=S group, NH group, and C=O of thiazol ring, but band due to the SH group at 2560 cm⁻¹ is observed. The tautomeric equilibrium between iminothiol- $\mathbf{6}\alpha$ and thioamide-form $\mathbf{6}\beta$ seems to be widely shifted toward the iminothiol form as indicated by the ¹H NMR spectrum which revealed a signlet at δ 7.85 ppm assigned to the -N-(C=N-)-SH group and this peak disappear on addition of deuterium oxide. Structure 6a was further confirmed by ¹³C NMR spectrum which gave conclusive evidence for iminothiol-form 6α . The spectrum reveals low-field signal at 154.4 (triazole C-2), 59.2 ppm (spiro carbon) and the other signals appeared at expected field (Figure 1). If the thioamide-form $\mathbf{6}\beta$ is the reaction product, one would expect a signal for the triazole C-2 to appeare at higher values (see Experimental). The formation of **6a** involves intramolecular heterocyclization of **5**, thus the reaction of **5** with NaOH furnishes¹⁸ the ambident N,S anion, the terminal nitrogen of which attacks the carbonyl carbon of 1,3-thiazole ring to yield the corresponding 6. Compounds 6b,c were prepared in similar way (Scheme 1). The structure of **6b**,**c** were confirmed on the same line as **6a** (see Experimental).

EXPERIMENTAL

All mps were recorded on a Gallen Kamp apparatus and are uncorrected. IR spectra (cm⁻¹) were recorded (as KBr pellets) on a Shimadzu 480 spectrophotometer. The ¹H NMR spectra were measured in DMSO-d₆ with a Bruker AM 400 (400 MHz) spectrometer using TMS as an internal standard; the ¹³C NMR spectra were recorded at 100 MHz.

The chemical shifts are expressed as δ values (ppm). Mass spectra were determined on a Finnigan Mat 8430 mass spectrometer operating at 70 eV. Microanalytical data were obtained from Microanalytical unit at Cairo University. Compound **1** was prepared by literature¹⁹ and the starting materials were obtained commercially.

General Procedure for the Synthesis of 1-Cycloalkylidene-4-(2,3-dimethyl-1-phenyl-pyrazolone-5-yl-4)-thiosemicarbazones 3a-c

The thiosemicarbazide **1** (0.01 mmol) was dissolved in 20 ml of hot butanol, then cycloalkanones **2a–c** (0.01 mmol) and 1 ml of acetic acid were added and the mixture was refluxed for about 4–6 h. After cooling, the resulting product was filtered off, washed with butanol and diethyl ether, and recrystallized from AcOH/H₂O (1:1).

1-Cyclohexaylidene-4-(2,3-dimethyl-1-phenyl-pyrazolone-5-yl-4)-thiosemicarbazone (3a)

Obtained in 80% yield, m.p. 214–216°C; (found: C, 60.40; H, 6.50; N, 19.60; S, 8.90. $C_{18}H_{23}N_5OS$ requires C, 60.48; H, 6.49; N, 19.59; S, 8.97%); υ_{max}/cm^{-1} 3320–3150 (NH) 2900,2850 (–CH₂–), 1650 (CO), 1620 (C=N), 1220 (C=S); $\delta_{\rm H}$ 1.41–2.10 (m, 10H, cyclohexyl protons), 2.17 (s, 3H,CH₃), 3.09 (s, 3H, N–CH₃), 7.2–7.6 (m, 5H, Ar–H), 9.3 (s, 1H, NH), 11.90 (s, 1H, NH); $\delta_{\rm C}$ 15.7, 26.2, 27.0, 32.2, 33.1, 35.5, 112.2, 116.5, 118.8, 129.0, 131.6, 142.4, 156.0, 160.8, 178.4; m/z 357 (M⁺, 74%).

1-(2-Methyl-cyclohexaylidene)-4-(2,3-dimethyl-1phenylpyrazolone-5-yl-4)-thiosemicarbazone (3b)

Obtained in 78% yield, m.p. 206–208°C; (found: C, 61.50; H, 6.80; N, 18.90; S, 8.50. $C_{19}H_{25}N_5OS$ requires C, 61.43; H, 6.78; N, 18.85; S, 8.63%); υ_{max}/cm^{-1} 3300–3150 (NH), 2900,2850 (–CH₂–), 1650 (CO), 1620 (C=N), 1220 (C=S); δ_H 0.78 (d, J 6.5 Hz, 3H, CH₃), 1.43–2.11 (m, 8H, cyclohexyl protons), 2.19 (s, 3H, CH₃), 2.23 (m, 1H, CH), 3.10 (s, 3H, N–CH₃), 7.2–7.5 (m, 5H, Ar–H), 9.40 (s, 1H, NH), 11.80 (s, 1H, NH); m/z 371 (M⁺, 89%).

1-Cycloheptaylidene-4-(2,3-dimethyl-1-phenyl-pyrazolone-5-yl-4)-thiosemicarbazone (3c)

Obtained in 68% yield, m.p. 208–210°C; (found: C, 61.50; H, 6.80; N, 18.80; S, 8.60. $C_{19}H_{25}N_5OS$ requires C, 61.43; H, 6.78; N, 18.85; S, 8.63%); ν_{max}/cm^{-1} 3320–3150 (NH) 2900,2850 (–CH₂–), 1650 (CO), 1620 (C=N), 1220 (C=S); $\delta_{\rm H}$ 1.61–2.10 (m, 12H, cycloheptyl protons),

2.15 (s, 3H,CH₃), 3.10 (s, 3H, N–CH₃), 7.2–7.5 (m, 5H, Ar–H), 9.3 (s, 1H, NH), 11.8 (s, 1H, NH); m/z 371 (M⁺, 72%).

Synthesis of Spirothiazolidinones 5a-c

To a well stirred solution of **3a–c** (0.05 mmol) in dry dioxane (50 ml) was added mercaptoacetic acid (4) (0.075 mmol). The reaction mixture was refluxed for 6–8 h (monitored by TLC). The clear solution thus obtained was allowed to cool, poured into ice-cold water, and neutrallized with NaHCO₃. The crystalline product thus formed was filtered off, washed with water, and recrystallized from dioxane.

4-[3-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4))thioureido]-1-thia-4-azaspiro-[4.5]-decan-3-one (5a)

Obtained in 64% yield, m.p. 262–263°C; (found: C, 55.70; H, 5.90; N, 16.30; S, 14.80. C₂₀H₂₅N₅O₂S₂ requires C, 55.66; H, 5.84; N, 16.23; S, 14.86%); v_{max} /cm⁻¹ 3320–3150 (NH) 2900, 2850 (–CH₂–), 1685, 1650 (CO), 1620 (C=N), 1220 (C=S); δ_{H} 1.15–2.10 (m, 10H, cyclohexyl protons), 2.15 (s, 3H, CH₃), 3.09 (s, 3H, N–CH₃), 3.52 (s, 2H, thiazolidinone protons), 7.2–7.4 (m, 5H, Ar–H), 11.9 (br, s, 2 NH); δ_{C} 15.8, 19.5, 27.4, 34.5, 35.5, 43.6, 53.5, 112.2, 116.4, 118.8, 128.8, 131.6, 142.4, 160.8, 164.6, 178.4; m/z 431 (M⁺, 78%).

4-[3-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4))thioureido]-6-methyl-1-thia-4-aza-spiro[4.5]decan-3-one (5b)

Obtained in 65% yield, m.p. 242–243°C; (found: C, 56.50; H, 6.20; N, 15.80; S, 14.30. $C_{21}H_{27}N_5O_2S_2$ requires C, 56.60; H, 6.11; N, 15.72; S, 14.39%); v_{max}/cm^{-1} 3320–3150 (NH) 2900, 2850 (–CH₂–), 1685, 1650 (CO), 1620 (C=N), 1220 (C=S); $\delta_{\rm H}$ 0.80 (d, J 6.5 Hz, 3H, CH₃), 1.15–2.10 (m, 8H, cyclohexyl protons), 2.15 (s, 3H, CH₃), 2.25 (m, 1H, CH), 3.15 (s, 3H, N–CH₃), 3.46 (s, 2H, thiazolidinone protons), 7.2–7.6 (m, 5H, Ar–H), 11.8 (br, s, 2 NH); m/z 445 (M⁺, 80%).

4-[3-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4))thioureido]-1-thia-4-azaspiro-[4.6]-undecan-3-one (5c)

Obtained in 61% yield, m.p. 252–254°C; (found: C, 56.50; H, 6.00; N, 15.70; S, 14.40. $C_{21}H_{27}N_5O_2S_2$ requires C, 56.60; H, 6.11; N, 15.72; S, 14.39%); υ_{max}/cm^{-1} 3320–3150 (NH) 2900, 2850 (–CH₂–), 1680, 1650 (CO), 1620 (C=N), 1220 (C=S); $\delta_{\rm H}$ 1.61–2.10 (m, 12H, cycloheptyl protons), 2.17 (s, 3H, CH₃), 3.10 (s, 3H, N–CH₃), 3.49 (s, 2H, thiazolidinone protons), 7.2–7.6 (m, 5H, Ar–H), 11.9 (br, s, 2 NH); m/z 445 (M⁺, 82%).

Synthesis of 1-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4)-2-mercapto-1',5-cycloalkane-spiro[1,3]thiazolo[3,4-b]-1,2,4triazoles 6a-c

To a solution of NaOH (0.01 mmol) in methanol (30 ml), spirothiazolidinone **5a–c** (0.01 mmol) was added and the mixture was refluxed for 5–6 h. The solid was then collected while hot, and poured in water (50 ml), the mixture was acidified with concentrated hydrochloric acid and stirred for 1 h. The precipitated solid was filtered off, washed with water, and disolved in the minimum volume of acetone. The residue was sujected to PLC chromatography using tolune-ethylacetate (3:2) as eluent. The pure products were recrystallized from dioxane.

1-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4)-2-mercapto-1',5-cyclohexane-spiro[1,3]thiazolo-[3,4-b]-1,2,4-triazole (6a)

Obtained in 64% yield, m.p. 276–278°C; (found: C, 58.20; H, 5.50; N, 17.00; S, 15.40. $C_{20}H_{23}N_5OS_2$ requires C, 58.09; H, 5.61; N, 16.93; S, 15.51%); υ_{max}/cm^{-1} 2900, 2850 (–CH₂–), 2560 (SH), 1650 (CO), 1620 (C=N); $\delta_{\rm H}$ 1.12–2.10 (m, 10H, cyclohexyl protons), 2.15 (s, 3H, CH₃), 3.20 (s, 3H, N–CH₃), 7.2–7.7 (m, 6H, Ar–H and CH), 7.85 (s, 1H, SH); $\delta_{\rm C}$ 15.8, 18.8, 26.6, 35.5, 37.2, 59.2, 84.2, 106.1, 112.2, 118.8, 129.0, 131.8, 137.4, 142,4, 154.4, 160.8; m/z 413 (M⁺, 72%).

1-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4)-2-mercapto-1',5-(2'-methyl-cyclohexane)-spiro[1,3]thiazolo[3,4-b]-1,2,4-triazole (6b)

Obtained in 60% yield, m.p. 266–268°C; (found: C, 59.00; H, 5.80; N, 16.50; S, 14.90. $C_{21}H_{25}N_5OS_2$ requires C, 58.99; H, 5.89; N, 16.38; S, 15.00%); v_{max}/cm^{-1} 2900, 2850 (–CH₂–), 2565 (SH), 1650 (CO), 1620 (C=N); $\delta_{\rm H}$ 0.79 (d, J 6.5 Hz, 3H, CH₃), 1.23–2.13 (m, 8H, cyclohexyl protons), 2.15 (s, 3H, CH₃), 2.29 (m, 1H, CH), 3.15 (s, 3H, N–CH₃), 7.2–7.7 (m, 6H, Ar–H and CH), 7.85 (s, 1H, SH); m/z 427 (M⁺, 76%).

1-(2,3-Dimethyl-1-phenyl-pyrazolone-5-yl-4)-2-mercapto-1',5-cycloheptane-spiro[1,3]-thiazolo-[3,4-b]-1,2,4-triazole (6c)

Obtained in 60% yield, m.p. 270–272°C; (found: C, 58.90; H, 6.00; N, 16.40; S, 15.00. $C_{21}H_{25}N_5OS_2$ requires C, 58.99; H, 5.89; N, 16.38; S, 15.00%); v_{max}/cm^{-1} 2900, 2850 (–CH₂–), 2560 (SH), 1650 (CO), 1620 (C=N); δ_H 1.61–2.20 (m, 12H, cycloheptyl protons), 2.15 (s, 3H, CH₃), 3.20 (s, 3H, N–CH₃), 7.2–7.7 (m, 6H, Ar–H and CH), 7.85 (s, 1H, SH); m/z 427 (M⁺, 82%).

REFERENCES

- [1] J. L. Bullington and J. H. Dood, J. Heterocycl. Chem., 35, 397 (1998).
- [2] T. Nagasaka, H. Sato, and S. I. Saeki, Tetrahedron Asymmetry, 8, 191 (1997).
- [3] M. T. Crimmins, D. G. Washburn, J. D. Katz, and F. J. Zawacki, *Tetrahedron Lett.*, 39, 3439 (1998).
- [4] H. Pellissier, P. Y. Michellys, and M. Santelli, J. Org. Chem., 62, 5588 (1995).
- [5] J. A. Wendt, P. J. Gauvreau, and R. D. Bach, J. Am. Chem. Soc., 116, 992 (1994).
- [6] H. Eto, Y. Kaneko, and T. Sakamotoa, Pharm. Bull., 48(7), 982 (2000).
- [7] M. C. Hosur, M. B. Talawar, U. V. Laddi, R. S. Bennur, and S. C. Bennur, *Indian J. Chem.*, 34B, 707 (1995).
- [8] L. Czollner, G. Szilagyi, J. Lango, and J. Janaky, Arch. Pharm. (Weinheim, Ger.) 323, 225 (1990).
- [9] R. M. Jacobson and L. T. Nguyen, Eur. Pat. Appl. Ep. 338 685 (1990); C.A. 112, 178991t (1990).
- [10] M. V. Diurno, O. Mazzoni, E. Piscopo, and A. Bolognese, Farmaco. 48, 435 (1993).
- [11] R. G. Mehta, J. Liu, A. Constantinou, M. Hawthorne, J. M. Pezzuto, R. C. Moon, and R. M. Moriarty, *Anticancer Res.*, 14, 1209 (1994).
- [12] R. M. Shaker, Phosphorus, Sulfur, and Silicon 149, 7 (1999).
- [13] R. M. Shaker, Die pharmazie 148 (1996).
- [14] R. M. Shaker and F. F. Abdel-Latif, J. Chem. Res.(S) 294 (1997).
- [15] R. A. Mekheimer and R. M. Shaker, J. Chem. Res. (S) 76 (1999); (M), 0449 (1999).
- [16] R. M. Shaker, Phosphorus, Sulfur, and Silicon 158, 9 (2000).
- [17] R. M. Shaker, A. F. Mahmoud, and F. F. Abdel-Latif, *Phosphorus, Sulfur, and Silicon* 160, 207 (2000).
- [18] I. Ya. Postovskii, and N. N. Vereshchagina, *Zhur. Obschchei Khim.* 26, 2583 (1956); C.A. 51, 5055b (1956).
- [19] M. Morita, Yakugaku Zasshi. 82, 36 (1962); C.A. 57, 16586d (1962).